Scientists wishing to use telomerase-immortalized cell lines for biological research, including applications such as drug screening and toxicity tests, can now obtain them through drug-discovery product and services firm Cambrex via a non-exclusive, worldwide licensing pact with Geron that the companies signed last week.

Under the terms of the agreement, Cambrex Bio Science Walkersville, a subsidiary of Cambrex, will develop and distribute cell lines that have been immortalized using Geron’s patented telomerase technology.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.